SCHEMBL23923444

SCHEMBL23923444

C[C@@H]1C[C@H]1c1cccc(O)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
HTR2B P41595 1/20 0.56
CHRNB4 P30926 1/20 0.53
CHRNA3 P32297 1/20 0.53
CA12 O43570 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CA2 P00918 1/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
KDM1A O60341 2/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23940041 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL30317799 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL23923588 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL23923443 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL30317790 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3
Ammonia Solution, Strong SCHEMBL266151 0.98 HTR2A (0.54) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL9419138 0.81 CHRNB4 (0.44) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL17263520 0.80 KDM1A (0.71) CYP3A4KDM1AHDAC6
SCHEMBL21066331 0.79 KDM1A (0.66) HTR2AHTR2CHTR2BCHRNB4CHRNA3
SCHEMBL8024246 0.79 HTR2C (0.56) HTR2AHTR2CHTR2BCHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-06-12 US disclosed
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds NOVARTIS AG (CH) 2025-04-29 US disclosed
CN-115867545-A Antiviral 1,3 dioxoindene compounds 诺华股份有限公司 2023-03-28 CN disclosed
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS NOVARTIS AG (CH) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188066-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885
US-20210323947-A1 ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS IRF3, EIF2AK2, ZC3HAV1 HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885
US-12286423-B2 Antiviral 1,3-di-oxo-indene compounds IRF3, EIF2AK2, ZC3HAV1 HTR2A 4358/4885HTR2C 3191/4885HTR2B 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.